Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Beloranib - Chong Kun Dang/ Larimar Therapeutics

Drug Profile

Beloranib - Chong Kun Dang/ Larimar Therapeutics

Alternative Names: 6-O-(4-dimethylaminoethoxy) cinnamoyl fumagillol hemioxalate; Beloranib hemioxalate; CKD-732; TNP-470 analogue; ZGN-433; ZGN-440

Latest Information Update: 05 Jun 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chong Kun Dang
  • Developer Chong Kun Dang; Zafgen
  • Class Antineoplastics; Cyclohexanes; Obesity therapies; Sesquiterpenes; Small molecules; Unsaturated fatty acids
  • Mechanism of Action Methionine aminopeptidase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Prader-Willi syndrome; Neuroectodermal tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Colorectal cancer; Obesity; Prader-Willi syndrome; Solid tumours

Most Recent Events

  • 29 May 2020 Chondrial Therapeutics has merged with Zafgen to form Larimar Therapeutics
  • 19 Jul 2016 Discontinued - Phase-I for Colorectal cancer (Combination therapy) in South Korea (IV)
  • 19 Jul 2016 Discontinued - Phase-I for Solid tumours in South Korea (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top